Molecular markers in prostate cancer. Part II: potential roles in management / 亚洲男科学杂志(英文版)
Asian Journal of Andrology
;
(6): 22-27, 2009.
Artigo
em Inglês
| WPRIM
| ID: wpr-284712
ABSTRACT
Predicting treatment responses in advanced prostate cancer (PCa) currently centres on prostate-specific antigen (PSA) kinetics and on being able to visualize measurable changes in imaging modalities. New molecular markers have emerged as potential diagnostic and prognostic indicators; these were summarized in Part I of this review in the Asian Journal of Andrology. A number of molecular markers are now being used to enhance PCa imaging and staging. However, management options for advanced and hormone-resistant PCa (HRPC) are limited and additional therapeutic options are needed. Molecular markers have been proposed as potential therapeutic targets using gene therapy and immunomodulation. Additionally, markers identified in early PCa and precursor lesions may offer novel targets for chemoprevention and vaccine development. This review summarizes the current advances regarding the roles of these markers in the management of PCa.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias da Próstata
/
Terapêutica
/
Sangue
/
Terapia Genética
/
Biomarcadores Tumorais
/
Antígeno Prostático Específico
/
Vacinas Anticâncer
/
Usos Terapêuticos
/
Genética
/
Fatores Imunológicos
Tipo de estudo:
Estudo prognóstico
Limite:
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Asian Journal of Andrology
Ano de publicação:
2009
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS